^(131)I治疗Graves病合并白细胞减少的临床评价

Iodine-131 for the treatment of Graves disease complicated with leukopenia

目的:观察131I对Graves病(GD)合并白细胞减少患者治疗的疗效影响及安全性。方法:对131I治疗66例GD合并白细胞减少患者前后的游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)、白细胞水平及治愈率等临床资料进行回顾性分析。结果:GD合并白细胞减少患者经131I治疗3、6和12个月时的FT3和FT4水平与治疗前差异均有统计学意义(P<0.01);而治疗后1个月时的FT3、FT4及白细胞水平与治疗前差异均无统计学意义(P>0.05),治疗后6个月,治愈43例,白细胞恢复正常60例,好转6例。结论:GD合并白细胞减少患者经131I治疗后,随着GD的治愈,绝大多数GD合并白细胞减少患者白细胞恢复正常或明显改善,是一种安全有效的治疗方法。

Objective： To investigate the clinical effect and safety of iodine-131（^131I） in the treatment of Graves disease（ GD）complicated with leukopenia. Methods： Sixty-six cases of GD complicated with leukopenia were treated by131 I,and the levels of free triiodthyronine（ FT3）,free thyroxine（ FT4）,leukocyte and the curative effects were analyzed retrospectively. Results： The levels of FT3 and FT4 at 3,6 and 12 months after^131 I therapy reduced markedly（ P〈0. 01）,but there was no significant difference among FT3,FT4 or leukocyte at 1 month after^^131 I therapy（ P〈0. 05）. After 6 months＇ treatment,the GD in 43 cases were cured,the leukocyte in 60 cases returned normal and 6 cases improved. Conclusions： After the therapy of ^131 I,most of GD patients complicated with leukopenia are cured or turn better.^131 I therapy is effective and safe for the treatment of GD complicated with leukopenia.